The UK's Advertising Standards Authority, which has the power to ban individual promotional campaigns, has declared that an Australian clinic's London subsidiary offering treatment for male erectile dysfunction was "indirectly advertising a prescription-only medicine," a finding disputed by the Advanced Medical Institute, which plans to lodge an appeal.
The ASA received 522 complaints against billboard posters that appear to have been largely based on the presence of the word "sex" in the advertisement text. The Authority noted that this number would likely have been higher if it had not imposed a ban before conducting its investigation of the AMI's message.
Michael Spira, the firm's European chief medical officer, claimed that, "whilst the ASA has ruled that the advertisements promote prescription-only medication by using the phrase 'nasal delivery technology,' we believe that this ruling is not supported by the wording of the ASA's code."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze